Organon OGN Other Non-Opiod Pain, Bone and Dermatology — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's other non-opiod pain, bone and dermatology — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's other non-opiod pain, bone and dermatology — revenue?
- Organon (OGN) reported other non-opiod pain, bone and dermatology — revenue of $68M in Q1 2026.
- How has Organon's other non-opiod pain, bone and dermatology — revenue changed year-over-year?
- Organon's other non-opiod pain, bone and dermatology — revenue decreased by 0.0% year-over-year, from $68M to $68M.
- What is the long-term trend for Organon's other non-opiod pain, bone and dermatology — revenue?
- Over 4 years (2021 to 2025), Organon's other non-opiod pain, bone and dermatology — revenue has grown at a 1.0% compound annual growth rate (CAGR), from $288M to $300M.
- What does other non-opiod pain, bone and dermatology — revenue mean?
- This metric represents the total net sales generated from the company's portfolio of non-opioid pain management, bone health, and dermatological pharmaceutical products. It reflects the market demand and commercial performance of these specific therapeutic categories within the broader established medicines division. Monitoring this revenue stream helps investors assess the stability and growth trajectory of the company's legacy product lines outside of its core women's health and biosimilar focus areas.